[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"doc-detail-213121-en":3,"doc-seo-213121-105":30,"detail-sidebar-cat-0-en-105":92},{"code":4,"msg":5,"data":6},0,"success",{"doc_id":7,"user_id":8,"nickname":9,"user_avatar":10,"doc_module":4,"category_id":11,"category_name":12,"doc_title":13,"doc_description":14,"doc_content":15,"file_id":16,"file_url":17,"file_type":18,"file_size":19,"view_count":20,"is_deleted":4,"is_public":20,"is_downloadable":20,"audit_status":20,"page_count":21,"language":22,"language_code":23,"site_id":24,"html_lang":23,"table_of_contents":25,"faqs":26,"seo_title":27,"seo_description":14,"update_tm":28,"read_time":29},213121,3848291630094,"Emma Wilson","https://eur-avatar.wpscdn.com/davatar_085a072bc5b1113ac321206ff7593b45",7,"Healthcare","American Urological Association Guideline - Diagnosis and Treatment of Overactive Bladder (Non-Neurogenic) in Adults - AUA/SUFU Guideline","American Urological Association (AUA) guideline provides a clinical framework for diagnosing and treating non-neurogenic overactive bladder (OAB) in adults. It summarizes evidence from a systematic review and additional literature searches, and assigns evidence strength ratings when data are sufficient. The document outlines diagnostic principles, recommended evaluation components, and cautions against routine initial use of urodynamics and cystoscopy. It also details first- and second-line treatment steps, including behavioral therapy and anti-muscarinic options, with guidance on formulation choice, safety, and escalation.","Approved by the AUABoard of Directors May 2012  \nAuthors’ disclosure of potential conflicts of interest and author/staff contributions appear atthe end of the article.  \n© 2012 by the American Urological Association  \nThe Panel would like to acknowledge Martha M. Faraday, Ph.D., for her methodological expertise and invaluable contributions as well asthe Vanderbilt Evidencebased Practice Center for the preparation of the evidence report commissioned by the Agency for Healthcare Research and Quality (AHRQ).  \n1  \nAmerican Urological Association (AUA) Guideline  \nDIAGNOSIS AND TREATMENT OF OVERACTIVE BLADDER (Non-Neurogenic) IN ADULTS:  \nAUA/SUFU GUIDELINE  \nE. Ann Gormley, Deborah J. Lightner, Kathryn L. Burgio, Toby C. Chai, J. Quentin Clemens, Daniel J. Culkin, Anurag Kumar Das, Harris Emilio Foster, Jr., Harriette Miles Scarpero, Christopher D. Tessier, Sandip Prasan Vasavada  \nPurpose: The purpose of this guideline is to provide a clinical framework for the diagnosis and treatment of non-neurogenic overactive bladder (OAB) .  \nMethods: The primary source of evidence for this guideline was the systematic review and data extraction conducted as part of the Agency for Healthcare Research and Quality (AHRQ) Evidence Report/Technology Assessment Number 187 titled Treatment of Overactive Bladder in Women (2009) .1 That report searched PubMed, MEDLINE, EMBASE, and CINAHL for English-language studies published from January 1966 to October 2008 relevant to OAB. AUA conducted additional literature searches to capture treatments not covered in detail by the AHRQ report (e.g., intravesical onabotulinumtoxinA) and relevant articles published between October 2008 and December 2011. Insufficient evidence was retrieved regarding diagnosis; this portion of the guideline, therefore, is based on Clinical Principles and Expert Opinion. The review yielded an evidence base of 151 treatment articles after application of inclusion/exclusion criteria. These publications were used to create the majority of the treatment portion of the guideline. When sufficient evidence existed, the body of evidence for a particular treatment was assigned a strength rating of A (high), B (moderate) or C (low) . Additional treatment information is provided as Clinical Principles and Expert Opinion when insufficient evidence existed. See text and algorithm for definitionsand detailed diagnostic, management and treatment frameworks.  \nGuideline Statements  \nDiagnosis:  \n1. The clinician should engage in a diagnostic process to document symptoms and signs that characterize OAB and exclude other disorders that could be the cause of the patient’s symptoms; the minimum requirements for this process are a careful history, physical exam, and urinalysis. Clinical Principle  \n2. In some patients, additional procedures and measures may be necessary to validate an OAB diagnosis, exclude other disorders and fully inform the treatment plan. At the clinician’s discretion, a urine culture and/or post-void residual assessment may be performed and information from bladder diaries and/or symptom questionnaires may be obtained. Clinical Principle  \n3. Urodynamics, cystoscopy and diagnostic renal and bladder ultrasound should not be used in the initial workup of the uncomplicated patient. Clinical Principle  \n4. OAB is not a disease; it is a symptom complex that generally is not a lifethreatening condition. After assessment has been performed to exclude conditions requiring treatment and counseling, no treatment is an acceptable choice made by some patients and caregivers. Expert Opinion  \n5. Clinicians should provide education to patients regarding normal lower urinary tract function, what is known about OAB, the benefits vs. risks/burdens of the available treatment alternatives and the fact that acceptable symptom control may require trials of multiple therapeutic options before it is achieved. Clinical Principle  \nCopyright © 2012 American Urological Association Education and Research,","cbCaicEqrqZHj4Ur","https://ap.wps.com/l/cbCaicEqrqZHj4Ur","pdf",600656,1,36,"English","en",105,"# Purpose\n# Methods\n# Guideline Statements\n## Diagnosis\n## Treatment: First-Line Treatments\n## Treatment: Second-Line Treatments","[{\"question\":\"What are the minimum requirements for diagnosing non-neurogenic overactive bladder (OAB)?\",\"answer\":\"Clinicians should document symptoms and signs that characterize OAB and exclude other causes, using a careful history, physical exam, and urinalysis.\"},{\"question\":\"When might additional procedures or assessments be needed for an OAB diagnosis?\",\"answer\":\"Additional measures may be used to validate the diagnosis, exclude other disorders, and fully inform the treatment plan, including urine culture and/or post-void residual assessment, and information from bladder diaries and/or symptom questionnaires.\"},{\"question\":\"What are the recommended first-line and second-line treatments for OAB?\",\"answer\":\"First-line therapy is behavioral treatments such as bladder training, bladder control strategies, pelvic floor muscle training, and fluid management. Second-line therapy includes oral anti-muscarinics (with formulation preferences when available) and may include transdermal oxybutynin.\"}]","American Urological Association Guideline - Diagnosis and Treatment of Overactive Bladder (Non-Neurogenic) in Adults - AUA/SUFU Guideline | PDF",1788753898,91,{"code":4,"msg":31,"data":32},"ok",{"site_id":24,"language":23,"slug":33,"title":13,"keywords":34,"description":14,"schema_data":35,"social_meta":87,"head_meta":89,"extra_data":91,"updated_unix":28},"american-urological-association-guideline-diagnosis-and-treatment-of-overactive-bladder-non-neurogenic-in-adults-auasufu-guideline","",{"@graph":36,"@context":86},[37,54,69],{"@type":38,"itemListElement":39},"BreadcrumbList",[40,44,48,51],{"item":41,"name":42,"@type":43,"position":20},"https://docshare.wps.com","Home","ListItem",{"item":45,"name":46,"@type":43,"position":47},"https://docshare.wps.com/document/","Document",2,{"item":49,"name":12,"@type":43,"position":50},"https://docshare.wps.com/document/healthcare/",3,{"item":52,"name":13,"@type":43,"position":53},"https://docshare.wps.com/document/american-urological-association-guideline-diagnosis-and-treatment-of-overactive-bladder-non-neurogenic-in-adults-auasufu-guideline/213121/",4,{"url":52,"name":13,"@type":55,"author":56,"headline":13,"publisher":58,"fileFormat":61,"inLanguage":23,"description":14,"dateModified":62,"datePublished":63,"encodingFormat":61,"isAccessibleForFree":64,"interactionStatistic":65},"DigitalDocument",{"name":9,"@type":57},"Person",{"url":41,"name":59,"@type":60},"DocShare","Organization","application/pdf","2026-09-11","2026-09-07",true,{"@type":66,"interactionType":67,"userInteractionCount":20},"InteractionCounter",{"@type":68},"ViewAction",{"@type":70,"mainEntity":71},"FAQPage",[72,78,82],{"name":73,"@type":74,"acceptedAnswer":75},"What are the minimum requirements for diagnosing non-neurogenic overactive bladder (OAB)?","Question",{"text":76,"@type":77},"Clinicians should document symptoms and signs that characterize OAB and exclude other causes, using a careful history, physical exam, and urinalysis.","Answer",{"name":79,"@type":74,"acceptedAnswer":80},"When might additional procedures or assessments be needed for an OAB diagnosis?",{"text":81,"@type":77},"Additional measures may be used to validate the diagnosis, exclude other disorders, and fully inform the treatment plan, including urine culture and/or post-void residual assessment, and information from bladder diaries and/or symptom questionnaires.",{"name":83,"@type":74,"acceptedAnswer":84},"What are the recommended first-line and second-line treatments for OAB?",{"text":85,"@type":77},"First-line therapy is behavioral treatments such as bladder training, bladder control strategies, pelvic floor muscle training, and fluid management. Second-line therapy includes oral anti-muscarinics (with formulation preferences when available) and may include transdermal oxybutynin.","https://schema.org",{"og:url":52,"og:type":88,"og:title":13,"og:site_name":59,"og:description":14},"article",{"robots":90,"canonical":52},"index,follow",{"doc_id":7,"site_id":24},{"code":4,"msg":5,"data":93},[94,98,102,106,111,116,119,124,129,132,136],{"id":20,"doc_module":4,"doc_module_name":46,"category_name":95,"show_sort_weight":96,"slug":97},"Story & Novel",90,"story-novel",{"id":47,"doc_module":4,"doc_module_name":46,"category_name":99,"show_sort_weight":100,"slug":101},"Literature",80,"literature",{"id":53,"doc_module":4,"doc_module_name":46,"category_name":103,"show_sort_weight":104,"slug":105},"Exam",70,"exam",{"id":107,"doc_module":4,"doc_module_name":46,"category_name":108,"show_sort_weight":109,"slug":110},5,"Comic",60,"comic",{"id":112,"doc_module":4,"doc_module_name":46,"category_name":113,"show_sort_weight":114,"slug":115},6,"Technology",50,"technology",{"id":11,"doc_module":4,"doc_module_name":46,"category_name":12,"show_sort_weight":117,"slug":118},40,"healthcare",{"id":120,"doc_module":4,"doc_module_name":46,"category_name":121,"show_sort_weight":122,"slug":123},8,"Research & Report",30,"research-report",{"id":125,"doc_module":4,"doc_module_name":46,"category_name":126,"show_sort_weight":127,"slug":128},9,"Religion & Spirituality",20,"religion-spirituality",{"id":127,"doc_module":4,"doc_module_name":46,"category_name":130,"show_sort_weight":127,"slug":131},"World Cup","world-cup",{"id":133,"doc_module":4,"doc_module_name":46,"category_name":134,"show_sort_weight":133,"slug":135},10,"Lifestyle","lifestyle",{"id":137,"doc_module":4,"doc_module_name":46,"category_name":138,"show_sort_weight":107,"slug":139},19,"General","general"]